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Abstract
Since 2000, the epidemiology of C. difﬁcile infections (CDI) has changed in the US and Europe. Few population-based assessments of
both incidence and case fatality of CDI have been performed. In this study, the Finnish nationwide laboratory-based surveillance data
from the year 2008 were analysed to assess the incidence and case fatality of CDI, and to detect regional differences in relation to
molecular epidemiology. A total of 6201 episodes of CDI were identiﬁed (118.3/100 000 population; range by regions, 57.2–189.1). The
incidence increased by age and was highest in persons aged >84 years (1286.0). Of the CDI episodes, 711 (11.5%; range by regions,
2.2–15.0%) led to death within 30 days. The 30-day case fatality was highest (22.0%) in persons aged >84 years. In total, 334 (5% of all
episodes) isolates from 13/21 regions were sent for genotyping: 120 (36%) were of PCR ribotype 027, and it was found in 6/13 regions.
Among the rest of the isolates, 53 (16%) were of type 001, and 19 (6%) of 002 and 014. The incidence and case fatality were highest in
elderly persons and varied regionally. This may be explained by uneven spread of hypervirulent PCR ribotypes, such as 027, but also dif-
ferences in diagnostic activity or the patient populations among which the outbreaks are occurring.
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Introduction
Clostridium difﬁcile is the most frequent cause of antibiotic-
associated diarrhoea. Recently, the epidemiology of C. difﬁcile
infections (CDI) has changed. Since 2000, CDI-related mor-
bidity and mortality have increased in North America as well
as in many parts of Europe [1–3]. Simultaneously, the emer-
gence of the hypervirulent PCR ribotype 027 was observed
and the virulence properties of the pathogen were charac-
terized. However, other PCR ribotypes may also have similar
genotypic virulence properties [4].
In Finland, hospitalizations with CDI doubled from 1996
to 2004 [5]. The increase was most notable for patients over
64 years of age. During 1998–2004, there was also a nearly
two-fold increase in CDI-associated mortality rate in the
same age group. The increase in these numbers might to
some extent be explained by the changes detected in diag-
nostic methodology [6]. Furthermore, in October 2007, the
ﬁrst case of CDI caused by the hypervirulent PCR ribotype
027 was reported in Finland [7]. In 2008 none of the Finnish
clinical microbiology laboratories performed routine cell cul-
ture cytotoxicity assays [6]. All of them used methods
detecting both toxins A (TcdA) and B (TcdB), and 87% used
both culture and toxin detection. In addition, three laborato-
ries were setting up a method to detect pathogenicity locus
genes by PCR for primary diagnostics.
In January 2008, toxin-positive CDI became a laboratory-
notiﬁable disease, and all clinical microbiology laboratories
were requested to send C. difﬁcile isolates from severe cases
and/or outbreaks to the National Institute for Health and
Welfare (THL) for genotyping. In Finland, the use of unique
personal identity codes enables the linkage of individual infor-
mation within National Infectious Disease Register (NIDR)
and other national databases, and to study the outcome of
illness systematically within a certain time interval. The
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objective of this study was to assess the incidence and case
fatality of CDI in Finland, and to detect regional differences
in CDI epidemiology based on the surveillance and genotyp-
ing data retrieved in 2008.
Materials and Methods
In Finland (population 5.3 million), the national healthcare
system is organized into 21 geographically and administra-
tively deﬁned healthcare districts (HDs), with populations
ranging from 67 800 to 1.7 million. Fifteen HDs have only
secondary and primary care hospitals, and ﬁve provide also
tertiary care services.
Laboratory-based epidemiological surveillance
Since 1 January 2008 all Finnish microbiology laboratories
have reported all C. difﬁcile ﬁndings (positive culture and/or
toxin production) from stools to the National Infectious Dis-
ease Register. Each notiﬁcation included the following infor-
mation: specimen date, each individual’s unique national
identity code, date of birth, sex and place of residence. Using
this information and a 3-month time interval, multiple notiﬁ-
cations of the same person were merged as a single episode.
An episode of CDI was deﬁned as detection of toxin-positive
C. difﬁcile from stools of persons aged ‡1 years. The dates of
deaths were obtained from the National Population Informa-
tion System by using the national identity code.
The data in this study were analysed within the epidemiolog-
ical research purposes authorized by the Finnish Contagious
Diseases Act (clause 4 in section 40 a, Finlex, Valtion sa¨a¨do¨stie-
topankki. Available at: http://www.ﬁnlex.ﬁ/ﬁ/laki/alkup/2003/
20030935. Accessed 16 April 2010).
Reference laboratory activities/molecular typing
In 2008, clinical microbiology laboratories were also asked to
send C. difﬁcile isolates from severe cases (CDI-related inten-
sive care, colectomy or death) [1,8,9] and outbreaks (‡3
C. difﬁcile cases within 4 weeks in the same unit) to the refer-
ence laboratory for genotyping. All the isolates obtained were
PCR ribotyped and classiﬁed according to the reason for
sending (severe case/outbreak/other reasons or unknown).
PCR ribotyping was performed according to the protocol
of the Anaerobe Reference Laboratory (ARL), Cardiff, UK
[10], using the Cardiff-ECDC culture collection as a set of
reference strains. After gel electrophoresis, the band pat-
terns were analysed using the BioNumerics 5.0 software
(Applied Maths NV, Sint-Martens-Latem, Belgium).
When a local outbreak was suspected, the isolates were
typed further using pulsed-ﬁeld gel electrophoresis (PFGE)
typing. The PFGE patterns were analysed by BioNumerics
using the Dice coefﬁcient to analyse the similarity of the
banding patterns, and the unweighted pair group method
using arithmetic averages (UPGMA) for cluster analysis.
Relatedness of ‡ 80% was used to deﬁne the lineages [11].
In addition, PaLoc-CDT- multiplex PCR was used for
detection of toxin genes tcdA, tcdB, cdtB and tcdC on selected
isolates. The primers for the PCR were designed based on
the published sequences of the pathogenicity locus (PaLoc)
and binary toxin CDT (cdtA and cdtB) genes of the C. difﬁcile
strains. The primers for the binary toxin were designed so
that the cdtB gene with the known deletion was not ampli-
ﬁed.
Incidence, case fatality and statistical analysis
Data from the National Population Information System for
the year 2007 were used as denominators to calculate age-
and sex-speciﬁc incidence rates, including rate ratios and
95% conﬁdence intervals. The case fatalities were calculated
by dividing all deaths due to any cause within 7 and 30 days
after positive diagnostic specimen for CDI, by the total num-
ber of CDI episodes. The genotyped isolates from severe
cases, outbreaks, and those of unknown or other reason for
sending were divided into two groups, type 027 and non-
027. To compare outcomes (30-day case fatality) between
the two groups, statistical comparison was only performed
among the outbreak-associated patients with CDI episode
and their isolates. The analyses between groups were carried
out by logistic regression using the R statistical software ver-
sion (R Development Core Team, Vienna, Austria) and con-
tinuous variables using the Mann–Whitney U-test.
Results
In 2008, 6201 episodes of CDI among 5717 individual
patients were identiﬁed; 4217 (68%) occurred in persons
aged >64 years and 3679 (59%) in female patients. The
annual incidence rate was 118.3 per 100 000 population. The
rate increased by age and was highest in persons aged
>84 years (1286.0 per 100 000 population) (Table 1). The
rate was higher in female patients than in male patients, but
the difference was statistically signiﬁcant only in persons aged
15–44 years. Of the CDI episodes, 259 (4.2%) led to death
within 7 days and 711 (11.5%) led to death within 30 days.
The 30-day case fatality was highest in persons aged
>84 years (22.0%) (Table 2). The 30-day case fatality was sig-
niﬁcantly higher in male patients than in female patients in
two age groups, persons aged 65–74 years and persons aged
75–84 years (p-values <0.01 and <0.05, respectively). The
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overall annual incidence varied regionally (range by 21 HDs,
57.2–189.1 per 100 000 population; Fig. 1), as well as the 30-
day case fatality (range by HDs, 2.2–15.0%).
In total, 334 (5% of all episodes) isolates (one per patient)
from 13/21 (62%) HDs were sent for genotyping (range in
number of isolates sent by HDs, 1–110; Fig. 1). Of these iso-
lates, 54 (16%) originated from severe cases, and 191 (57%)
from outbreaks. For the rest of the isolates (n = 89; 27%),
the reason for sending was either unknown or other (e.g.
screening for the hypervirulent PCR ribotype 027) (Table 3).
Of the isolates sent for genotyping, 120 (36%) were of
PCR ribotype 027, 53 (16%) were of PCR ribotype 001, 19
(6%) were of types 002 and 014, and 29 (9%) were of PCR
ribotypes other than type 027, which have deletions of
different sizes in their tcdC genes (i.e. 023, 045, 075, 078 and
126). Overall, 57 distinct PCR ribotype proﬁles were identi-
ﬁed. Among the 171 isolates analysed with both PFGE and
PCR ribotyping, 47 PFGE types were detected among 30
PCR ribotypes. On several occasions PCR ribotypes could
be divided further using PFGE typing (e.g. eight PFGE
(sub)types were detected within PCR ribotype 014). PCR
ribotype 027 was divided into ﬁve PFGE (sub)types (Fig. 2);
however, among one of them (NAP1 subtype1) three differ-
ent PCR ribotype proﬁles were identiﬁed (data not shown).
PCR ribotype 027 was found in 6/13 HDs (range, 1–42
isolates per HD), as well as the other ribotypes with tcdC
deletions. Type 027 was found in four HDs where the inci-
dences were among the ﬁve highest (range, 135.9–188.7 per
100 000 population), but also in two HDs with low incidence
(77.8 and 93.6 per 100 000 population). The HDs where
type 027 was found had the highest 30-day case fatalities
among the HDs that sent isolates for genotyping, with only
one exception (Fig. 1). There was no signiﬁcant correlation
between the ranks of HDs by incidence and case fatality
(correlation coefﬁcient, 0.23).
TABLE 2. Thirty-day case fatality of Clostridium difﬁcile
infection by age and sex, Finland, 2008
Age group (years)
Number of deaths at 30 days (case fatality,
%)
Female Male Total
1–14 0 (0) 2 (3.3) 2 (1.5)
15–44 0 (0) 5 (1.9) 5 (0.8)
45–64 26 (4.6) 36 (5.8) 62 (5.2)
65–74 30 (5.5) 64 (11.4) 94 (8.5)
75–84 148 (13.1) 122 (17.1) 270 (14.6)
>84 202 (20.9) 76 (25.6) 278 (22.0)
All 406 (11.1) 305 (12.1) 711 (11.5)
TABLE 1. Incidence of Clostridium difﬁcile infection by age
and sex, Finland, 2008
Age group
(years)
Incidencea (number of episodes)
Female Male
Rate
ratio 95% CI Total
1–14 18.6 (76) 14.3 (61) 1.3 0.9–1.8 16.4 (137)
15–44 39.9 (393) 25.3 (261) 1.6 1.3–1.8 32.4 (654)
45–64 75.0 (570) 82.5 (623) 0.9 0.8–1.0 78.7 (1193)
65–74 217.2 (543) 265.3 (564) 0.8 0.7–0.9 239.3 (1107)
75–84 577.4 (1131) 603.8 (715) 1.0 0.9–1.1 587.3 (1846)
>84 1308.6 (966) 1217.8 (298) 1.1 0.9–1.2 1286.0 (1264)
All 137.5 (3679) 98.3 (2522) 1.4 1.3–1.5 118.3 (6201)
CI, conﬁdence interval.
aEpisodes per 100 000 population.
FIG. 1. Annual incidence rate (episodes per 100 000 population) and case fatality (%) of Clostridium difﬁcile infection by healthcare district, and
the number of isolates sent for genotyping/PCR ribotype 027 found in 2008.
TABLE 3. Thirty-day case fatality of Clostridium difﬁcile
infection according to the reasons for sending isolates for
typing and PCR ribotypes, Finland, 2008
PCR ribotype
Case fatality, % (number of deaths/isolates sent)
Severe Outbreak Other
Type 027 30.4 (7/23) 23.2 (19/82) 13.3 (2/15)
Non-027 19.4 (6/31) 10.1 (11/109) 6.8 (5/74)
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Among the 334 patients with CDI episodes from whom
an isolate was sent for typing, the 30-day case fatality was
15.0% (Table 3). Type 027 was the most common ribotype
among severe cases (n = 23; 43%) and outbreaks (n = 82;
43%). The patients with CDI episodes caused by type 027
isolates were older than those with episodes caused by non-
027 isolates (median age 81.8 vs 77.0, respectively; p <0.01).
Among patients with CDI episodes related to outbreaks, the
30-day case fatality was higher when type 027 was isolated
(23.2% vs 10.1% for non-027 isolates; p <0.05). However,
when the age difference was taken into account by standardi-
zation, no statistically signiﬁcant difference was detected.
Discussion
Our study showed the ﬁrst nationwide estimates of inci-
dence and case fatality of CDI in Finland. Although many
regional and outbreak-related investigations have been
carried out, to our knowledge, this is the ﬁrst population-
based study on CDI incidence and case fatality.
In the current literature, most estimates of CDI incidence
available, especially from Europe, are proportioned per
patient-days or hospital discharges [3,12], and hence not
comparable with the results of this study. The observed
overall incidence of CDI in Finland (118.3/100 000 popula-
tion in 2008) was lower than in Quebec in 2003 [13]. How-
ever, in a couple of regions the rates were at a similar level.
In Quebec the CDI incidence rose from 35.6/100 000 popu-
lation to 156.3/100 000 in 1991–2003. The emergence of
PCR ribotype 027 might have contributed to the rise. In
Finland, the hospital discharges for which CDI was listed as
any diagnosis doubled from 1996 to 2004 [5]. According to a
recent Canadian report by Miller et al.[14] there was a
strong correlation between the presence of type 027 and
incidence of CDI when their data were analysed by province.
However, in our study no clear correlation between high
incidence and occurrence of PCR ribotype 027 was found
FIG. 2. Pulsed-ﬁeld gel electrophoresis (PFGE) dendrograms of Clostridium difﬁcile isolates. The scale bars at the top of the dendrograms indicate
similarity.
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regionally in 2008. The incidence rate was signiﬁcantly higher
in females than in males aged 15–44 years. This might be
explained by qualitatively or quantitatively differing antibiotic
consumption patterns between the genders (e.g. treatment
of urinary tract infections in women).
The overall 30-day case fatality proportion (11.5%) (i.e.
crude mortality rate) was lower than in Quebec in 2003
(13.8%) [13], although in four regions the proportion was
even higher. The regions where PCR ribotype 027 was found
seemed to suffer from higher 30-day case fatality. In concor-
dance with this, a relation between increased mortality and/or
more severe disease and type 027 has also been found in the
Netherlands and Quebec [15–17], but not in England [18].
The isolates from severe cases and suspected outbreaks
were genotyped to study the differences in virulence and epi-
demic potential of different ribotypes. Among the isolates
sent for genotyping, type 027 was the most prevalent PCR
ribotype, followed by types 001, 002 and 014. Type 027 was
the dominant PCR ribotype among the isolates from severe
cases and outbreaks. The number of cases was quite small,
but among these isolates the 30-day case fatality was more
than double for type 027 when compared with non-027
types. However, this difference was no longer statistically sig-
niﬁcant after age-standardization. This may imply that type
027 has a substantial effect on the elderly population because
they are likely to have more underlying illnesses. This is basi-
cally in concordance with the ﬁndings of Miller et al. [14],
who found a clear correlation between the presence of type
027 and more severe disease and outcomes among patients
aged 60–90 years.
We detected major regional variations in CDI incidence
and case fatality. According to a laboratory survey conducted
in 2006 and updated in 2008, the C. difﬁcile diagnostics meth-
odology is rather uniform in Finland [6]. Although our material
is nationally representative, there are some regions with low
incidence but high case fatality, which may be explained by a
lower diagnostic activity. Differences in diagnostic methodol-
ogy and sensitivity of the methods may also have an effect.
Indeed, the regions with laboratories using diagnostic PCR
assays had relatively high CDI incidences (i.e. second, ﬁfth and
sixth highest of the 21 regions). There are no accurate data
available for diagnostic activity in 2008, though in 2006 consid-
erable regional variation was detected [6]. The small number
of cases (and the relatively higher proportion of deaths) in
some small regions might also explain the differences.
Our aim was to support outbreak control measures
locally and detect strains with increased virulence properties
by genotyping isolates from severe cases and outbreaks. In
relation to methods used at the reference laboratory, having
more than one genotyping method proved useful in sorting
out local epidemics in hospital wards; generally, PFGE typing
was more discriminatory compared with PCR ribotyping, as
previously reported [19], with few exceptions. One of the
challenges is the question of how to select a representative
sample of isolates from all CDI cases for genotyping. The
simplest way would be to request the clinical microbiology
laboratories to send a predesignated proportion of C. difﬁcile
isolates (e.g. every tenth isolate) to the national reference
laboratory; however, in this study the aim was to understand
especially the genotypes and virulence factors of the isolates
associated with severe cases and support the hospitals strug-
gling with persistent C. difﬁcile problems. In Finland, it can be
argued that the data on molecular epidemiology of CDI in
2008 are not nationally representative because the isolates
were received from only 5% of the reported CDI cases.
Moreover, there was notable regional variation in numbers
of isolates. No isolates were sent from eight of the 21
regions, and unfortunately, the two regions with highest case
fatalities did not send any isolates at all. Either CDI is not
regarded as causing notable problems in these regions, or
genotyping is seen as useless in solving these issues, or the
criteria for sending isolates are considered too strict. The
problem may lie in the ﬂow of information between the
laboratory and the clinic: an indication about severe disease/
suspected outbreak is usually not included in the background
information on the samples received by the clinical laborato-
ries. In addition, the deﬁnition of an outbreak and the
threshold for reaction might vary between hospitals. The
30-day case fatality was 15% among the cases from which
isolates were received, compared with the overall case fatal-
ity rate of all the cases reported to the NIDR (11.5%).
In conclusion, CDI affected mostly elderly people. The
incidence and 30-day case fatality were highest in persons
aged >84 years. The overall incidence and case fatality varied
regionally. PCR ribotype 027 seemed to be associated with
higher case fatality than the non-027 ribotypes. However,
much of this can be explained by the settings and patient
populations where the outbreaks are occurring.
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